Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Stock Holdings Boosted by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC lifted its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 146.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 366,444 shares of the biopharmaceutical company's stock after buying an additional 217,956 shares during the period. Allspring Global Investments Holdings LLC owned approximately 0.31% of Catalyst Pharmaceuticals worth $7,285,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of CPRX. GAMMA Investing LLC boosted its position in shares of Catalyst Pharmaceuticals by 62.1% in the third quarter. GAMMA Investing LLC now owns 1,778 shares of the biopharmaceutical company's stock worth $35,000 after buying an additional 681 shares during the period. nVerses Capital LLC acquired a new position in shares of Catalyst Pharmaceuticals in the third quarter worth about $50,000. CWM LLC lifted its stake in shares of Catalyst Pharmaceuticals by 686.5% in the second quarter. CWM LLC now owns 4,066 shares of the biopharmaceutical company's stock worth $63,000 after acquiring an additional 3,549 shares in the last quarter. Meeder Asset Management Inc. acquired a new position in shares of Catalyst Pharmaceuticals in the second quarter worth about $70,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Catalyst Pharmaceuticals in the second quarter worth about $153,000. Hedge funds and other institutional investors own 79.22% of the company's stock.

Insider Activity

In other news, insider Steve Miller sold 150,000 shares of the company's stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $20.35, for a total transaction of $3,052,500.00. Following the completion of the transaction, the insider now directly owns 675,124 shares of the company's stock, valued at approximately $13,738,773.40. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, insider Carmen Jeffrey Del sold 36,058 shares of the stock in a transaction that occurred on Friday, August 9th. The stock was sold at an average price of $18.42, for a total value of $664,188.36. Following the completion of the transaction, the insider now directly owns 12,369 shares of the company's stock, valued at $227,836.98. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Steve Miller sold 150,000 shares of the stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $20.35, for a total value of $3,052,500.00. Following the completion of the transaction, the insider now directly owns 675,124 shares of the company's stock, valued at $13,738,773.40. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 201,058 shares of company stock valued at $4,018,188. 11.00% of the stock is currently owned by insiders.

Analyst Ratings Changes

CPRX has been the topic of several recent analyst reports. HC Wainwright boosted their price target on Catalyst Pharmaceuticals from $26.00 to $30.00 and gave the stock a "buy" rating in a research note on Monday, August 12th. Truist Financial boosted their price target on Catalyst Pharmaceuticals from $25.00 to $30.00 and gave the stock a "buy" rating in a research note on Friday, August 9th. Citigroup upped their price objective on Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the company a "buy" rating in a research note on Friday, August 9th. Finally, StockNews.com upgraded Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Friday, August 9th. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, Catalyst Pharmaceuticals has a consensus rating of "Buy" and an average price target of $29.50.

Catalyst Pharmaceuticals Trading Up 1.9 %

NASDAQ CPRX traded up $0.40 on Monday, hitting $21.86. 670,028 shares of the stock traded hands, compared to its average volume of 1,196,945. The company has a market capitalization of $2.58 billion, a P/E ratio of 40.69, a price-to-earnings-growth ratio of 3.18 and a beta of 0.76. The stock has a 50-day moving average of $20.37 and a 200 day moving average of $17.62. Catalyst Pharmaceuticals, Inc. has a twelve month low of $11.89 and a twelve month high of $22.20.

Catalyst Pharmaceuticals (NASDAQ:CPRX - Get Free Report) last posted its earnings results on Wednesday, August 7th. The biopharmaceutical company reported $0.52 EPS for the quarter, beating the consensus estimate of $0.39 by $0.13. The company had revenue of $122.71 million during the quarter, compared to analyst estimates of $111.76 million. Catalyst Pharmaceuticals had a return on equity of 27.77% and a net margin of 15.69%. As a group, equities research analysts expect that Catalyst Pharmaceuticals, Inc. will post 1.82 earnings per share for the current year.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.